Rochester, NY 7/10/2009 10:39:41 PM
WhisperfromWallStreet.com Stock Report - PLX - Protalix Is Asked to Widen Gaucher-Drug Supply
Protalix BioTherapeutics, Inc.
WhisperfromWallStreet.com Stock Report - PLX - Protalix Is Asked to Widen Gaucher-Drug Supply
---
Protalix BioTherapeutics, Inc.,PLX
Last Trade: 4.82
Day's Range: 4.72 - 4.85
52wk Range: N/A
Volume: 37,526
Protalix BioTherapeutics Inc. said Monday it has been approached by the Food and Drug Administration to consider submitting a treatment protocol of its lead drug candidate for patients with Gaucher disease.
4.73 Down 0.12 (2.47%) 10:54AM ET
ABOUT THE COMPANY
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. Its lead product candidate includes prGCD, a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme for the treatment of Gaucher disease, which is in Phase III clinical trial. The company also develops PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart, and other organs; a proprietary plant cell-based acetylcholinestrase and its molecular variants for use in various therapeutic and prophylactic indications, including a Biodefense program; and an organophosphate-based pesticide treatment program.
---
There are hundreds of stocks that rise and fall each day, our expertise is understanding which have the best opportunity for rapid growth. Our newsletter has sent out over 40 alerts this year with an average price gain of 80%. If you like to be alerted to the stocks that meets our criteria. Please join us for free to track our results.
You can sign up now for free stock alerts at WhisperfromWallStreet.com
---
Please read the COMPLETE DISCLAIMER posted on our website.
IMPORTANT NOTE: This is not a solicitation to buy or sell any securities. Neither WhisperfromWallStreet.com, nor any of its affiliates are registered investment advisors or a broker dealer. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
